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Structure of CD40 Ligand in Complex with the Fab
Fragment of a Neutralizing Humanized Antibody
types such as monocytes and endothelial, epithelial,
and dendritic cells. CD40L is a type II membrane glyco-
protein that has been found to be expressed on the
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Biogen, Inc. surface of different cell types, including activated CD41
T cells. These cells mediate a signal to B cells through14 Cambridge Center
Cambridge, Massachusetts 02142 the CD40-CD40L interaction, which results in B cell acti-
vation. The effects of B cell activation include antibody
isotype switching, rescue from apoptosis, germinal cen-
ter formation, and B cell differentiation and proliferationSummary
[3]. Mutations in the gene encoding for CD40L result in
a severe X-linked immunodeficiency, known as hyper-Background: CD40 ligand (CD40L or CD154), a mem-
ber of the tumor necrosis factor (TNF) family, plays a IgM Syndrome (HIGMS), that is characterized by normal
or elevated serum levels of IgM and low serum levelscritical role in both humoral and cellular immune re-
sponses and has been implicated in biological pathways of IgG, IgA, and IgE [4]. A similar phenotype is observed
for a murine CD40L-knockout mouse. These observa-involving epithelial cells, fibroblasts, and platelets. Such
a pathway is T cell-mediated B cell activation, a process tions suggest that CD40L has a central role in driving B
cells to undergo antibody isotype switching, a processthat occurs through the interaction of CD40L with CD40
receptor expressed on B cells. It results in various B cell that is essential for normal immune response. Because
the control of immune response is desirable in manyresponses, including immunoglobulin isotype switching
and B cell differentiation and proliferation. These re- medical conditions such as autoimmune diseases,
acute inflammation, and transplant rejection, inhibitionsponses can be inhibited by the monoclonal antibody
5c8, which binds with high affinity to CD40L. of the CD40L-CD40 pathway is an attractive possibility
for pharmaceutical treatment [5]. Indeed, monoclonal
antibodies that inhibit CD40L have shown promise inResults: To understand the structural basis of the inhi-
bition, we determined the crystal structure of the com- animal models for lupus nephritis [6] and transplant re-
jection [7, 8].plex of the extracellular domain of CD40L and the Fab
fragment of humanized 5c8 antibody. The structure CD40L and CD40 are members of the tumor necrosis
factor (TNF) family of ligands and receptors, respec-shows that the complex has the shape of a three-bladed
propeller with three Fab fragments bound symmetrically tively. The family of TNF-like ligands includes, among
others, TNF-a, lymphotoxin-a (LT-a), lymphotoxin-b,to a CD40L homotrimer. To further study the nature of
the antibody-antigen interface, we assessed the ability Fas ligand, and Apo2L/TRAIL. The full-length CD40L is
a trimeric molecule that includes a globular extracellularof 23 site-directed mutants of CD40L to bind to 5c8 and
CD40 and analyzed the results in the context of the TNF-homologous domain, a long extracellular stalk, a
short transmembrane segment, and a small cytoplasmiccrystal structure. Finally, we observed via confocal mi-
croscopy that 5c8 binding to CD40L on the cell surface domain. It has been shown that two shorter forms of
this protein also exist that can assemble with the full-results in the formation of patches of clustered com-
plexes. length form as heterotrimers [9]. The crystal structure
of the globular part of the extracellular domain has been
determined [10] and shows that each monomer adoptsConclusions: The structure reveals that 5c8 neutralizes
CD40L function by sterically blocking CD40 binding. The the b sheet sandwich fold that characterizes the mem-
bers of the TNF family. The structure of the CD40 extra-antigenic epitope is localized in a region of the surface
that is likely to be structurally perturbed as a result of cellular domain has been modeled, based on the homol-
ogy to TNF receptor (TNFR) as an elongated moleculegenetic mutations that cause hyper-IgM syndrome. The
symmetric trimeric arrangement of the Fab fragments consisting of several tandem cysteine-rich repeats [11].
The binding site for CD40 has been located by modelingin the complex results in a geometry that facilitates the
formation of large clusters of complexes on the cell based on the crystal structure of the LT-a complex with
TNFR and mutagenesis experiments. It coincides with asurface.
shallow cleft that runs most of the length of the interface
between two adjacent monomers and includes residuesIntroduction
from both monomers [12]. The homologous structure of
LT-a in complex with a TNF receptor (TNFR) shows thatThe interaction of CD40 with CD40 ligand (CD40L or
CD154) has been shown to play a central role in the three TNFR molecules bind to the three available binding
sites of LT-a [13]. By analogy, it is believed that CD40Linitiation and maintenance of various humoral and cell-
mediated immune responses [1, 2]. CD40 is a cell sur- is signaling through the CD40 receptor by inducing a
similar trimeric arrangement of the CD40 receptor. How-face receptor that recently has been found to be ex-
pressed not only in B cells but in many different cell ever, experimental evidence suggests that higher-order
* To whom correspondence should be addressed (e-mail:
michael_karpusas@biogen.com). Key words: antigen; CD154; crystal structure; epitope; mutagenesis
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Figure 1. Stereoview of a Representative
Portion of the Final 2Fo-Fc Electron Den-
sity Map
The map is contoured at 1.2 s and superim-
posed on corresponding atoms from the final
refined model. The figure was made with
QUANTA.
assemblies of ligand and receptor molecules on the cell density is observed for the carbohydrate of CD40L but
is not of sufficient quality to allow modeling of carbohy-surface may also occur and may play important roles
drate residues. The stereochemistry is good (rmsd onin the function of TNF family members [14–16].
bond lengths is 0.014 A˚, and rmsd on bond angles isThe murine monoclonal antibody 5c8 binds strongly
1.898). The rms positional deviation between equivalentto CD40L and inhibits the CD40L-CD40 interaction. A
residues from different CD40L monomers or Fab frag-humanized version of this antibody was engineered and
ments is small (0.18 A˚ for main chain atoms) due to thewas used to study its therapeutic potential in extensive
use of noncrystallographic symmetry restraints duringanimal and human clinical studies. The antibody showed
most of the refinement process. All nonglycine residues,promise in inhibiting allograft rejection in primates and
except residue 183 of CD40L, are in the allowed regionsother animal models of disease. To develop a further
of the Ramachandran diagram. The average B factor ofunderstanding of the mechanism of inhibition by the 5c8
the main chain atoms is 18.8 A˚2. The constant domainsantibody, we crystallized the complex of CD40L with
of the Fab fragments have much higher B factors (aver-the Fab fragment of the humanized 5c8 and determined
age B factor is z29.5 A˚2) compared to the variable do-the crystal structure at 3.1 A˚ resolution. We further ana-
mains (average B factor is z14.1 A˚2). This appears tolyzed the nature of the antigenic epitope by site-directed
be a consequence of fewer crystal contacts for the con-mutagenesis of CD40L that involved alanine substitu-
stant domain of the Fab fragment compared to the vari-tions, charge reversal changes, and HIGMS mutations.
able domain. Crystallographic statistics are summarizedFinally, we studied the binding of hu5c8 to CD40L on
in Table 1.the cell surface using immunostaining and confocal mi-
The complex has the shape of a three-bladed propel-croscopy techniques. These experiments showed that
ler and consists of three Fab molecules radially bound5c8 induces clustering of CD40L in single patches or
on a single CD40L homotrimer (Figure 2). The dimen-“caps” on the cell surface, an effect that is consistent
sions of the complex are 140 3 140 3 60 A˚. The three-with the geometry of the complex, as observed in the
fold axis of the CD40L trimer coincides with the noncrys-crystal structure.
tallographic three-fold axis of the complex. The approxi-
mate pseudo two-fold axes of the Fab fragments, which
Results and Discussion relate the heavy and light chains, intersect the three-fold
symmetry axis of the complex and have an approximate
Structure of the 5c8 Fab-CD40L Complex angle of 308 upward to a plane that is perpendicular
The structure of the globular part of the CD40L extracel- to the three-fold axis. When we consider cell surface
lular domain (residues 116–261) complexed with the Fab CD40L, this plane is expected to coincide with the cell
fragment of the humanized 5c8 antibody was deter- surface.
mined at 3.1 A˚ resolution by molecular replacement and The crystallized CD40L fragment is a homotrimeric
refined to a crystallographic R value of 23.3% (Rfree 5 protein, and each monomer folds as a b sheet sandwich
28.5%). The asymmetric unit of the crystal contains a with Greek key topology. The overall shape of the trimer
single complex consisting of a CD40L homotrimer and resembles that of a truncated pyramid. The structure of
three Fab fragments. Almost all residues except N-termi- CD40L in the complex with the Fab is very similar to the
nal residues 116–118 of CD40L are well defined in the structure of the uncomplexed CD40L [10]. The A-A99
final 2Fo-Fc electron density map (Figure 1). The final loop of CD40L maintains the extended conformation
model consists of 1731 amino acid residues constituting that was observed originally and was not typical of other
9 polypeptide chains and 3 zinc ions. No water mole- members of the TNF family. It further suggests that this
conformation is real and not a consequence of crystalcules have been included in the model. Some electron
CD40L-5c8 Fab Complex Structure
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Table 1. Summary of Crystallographic Analysis
Data Collection
Cell dimensions a, b, c (A˚) 224.48, 129.91, 96.49
b (8) 109.62
Space group C2
Resolution (A˚) 35–3.1 (3.21–3.1)a
Unique reflections 46,508
Completeness (%) 96.1 (87.7)a
Average I/s 7.52 (1.97)a
Rmergeb (%) 7.6 (18.8)a
Model
Number of non-H atoms 16,203
Number of protein residues 1,731
Contents of asymmetric unit 3 Fab fragments, 1 CD40L trimer
Average B factor (A˚2) 18.8
Refinement
Resolution range used (F . 2s) 35–3.1




Bond lengths (A˚) 0.014
Angles (8) 1.89
a Values for the highest resolution shell given in parentheses.
b Rmerge 5 ShSijIhi 2 Ihj/ShiIhi.
contacts. Superimposition of uncomplexed CD40L tri-
mer (PDB entry 1aly) on the complexed CD40L trimer
shows that there are no significant conformational
changes of CD40L upon 5c8 binding (rmds is 0.76 A˚ for
Figure 2. The Crystal Structure of the CD40L-5c8 Fab Complex inmain chain atoms). The biggest differences (up to 4 A˚
Ribbon Representationshifts) are observed in the CD and EF loops of CD40L,
The top view is along the three-fold axis, while the bottom view iswhich are located at the “top” of the truncated pyramid,
perpendicular to the three-fold axis. The three CD40L monomers
away from the 5c8 epitope. These loops are known to are colored yellow, green, and dark blue. The three Fab heavy chains
be the most mobile regions of the CD40L moiety [10], are colored gray, dark gray, and magenta. The figure was made
and therefore the observed differences are not likely with RIBBONS [39].
to be a consequence of 5c8 binding. Some significant
differences, particularly compensatory rotamer shifts,
are observed for the side chains of a few residues of chain have canonical structures 1 and 2, respectively.
These are consistent with the canonical structures thatthe binding epitope, including the Y145 and R203 resi-
dues of CD40L that were shown to be important for would have been predicted based on sequence.
The interaction of a single Fab fragment with CD40LCD40 binding.
The Fab fragment is obtained from a humanized ver- buries a total solvent-accessible area of 771 A˚2 for
CD40L and 765 A˚2 for the 5c8 Fab, assuming that a 1.4 A˚sion of the original murine 5c8 antibody (Figure 3). The
humanized L chain construct was based on the human solvent probe was used. These values are similar to
the areas involved in typical antibody-antigen interac-subgroup III k chain from hybridoma AE6–5 [17]. The H
chain construct was based on the subgroup I 21/28CL tions but less than that of typical protein-protein interac-
tions [20, 21]. The antigenic epitope of 5c8 is locatedgene [18]. The modeled Fab structure consists of resi-
dues 1–219 of the heavy chain and residues 1–215 of on the right-hand side of the intersubunit cleft of CD40L
and is elongated and continuous. The long axis of thethe light chain. The variable domain of 5c8 Fab can
be superimposed on the variable domain of the anti- epitope footprint is parallel to the long axis of the CD40
binding site. Interestingly, although CD40L only existsp185HER2 antibody (PDB entry 1fvd) with an rms posi-
tional deviation of 1.36 A˚ for 1040 equivalent atoms. The as a trimer on the cell surface, the epitope is composed
only of residues from a single monomer of CD40L. Thecrystal structure of the uncomplexed Fab fragment of
5c8 has also been determined by us and will be de- epitope consists of residues E129, A130, S132, E142,
K143, G144, and Y146 of the A-A99 loop; C178 of the Cscribed elsewhere. The elbow angle of the complexed
Fab differs by 49.98 from that of the uncomplexed 5c8 strand; and C218, S245, Q246, S248, H249, and G250
of the G-H loop of CD40L. The antibody is using CDRFab. The CDR L1, CDR L2, and CDR L3 loops of the
light chain, comprising the complementarity-determin- H1, CDR H2, and CDR H3 hypervariable regions as well
as CDR L1 and CDR L3 to form contacts with CD40L.ing region, have canonical structures 3, 1, and 1, respec-
tively [19]. The CDR H1 and CDR H2 loops of the heavy This is consistent with the general observation that the
Structure
324
The epitope of 5c8 overlaps, but is not identical, with
the putative CD40 binding site. This is in agreement with
previous conclusions based on mutagenesis data [23].
For example, residues K143 and Y146, which have been
identified by mutagenesis to be important for the inter-
action of CD40L with CD40 [24, 11], are also involved
in interactions with 5c8. In particular, the K143 side chain
interacts with the side chain of N103(H) of 5c8 as well
as the main chain carbonyl of S95(L) of 5c8. Y146 inter-
acts with the S32(L) of the 5c8. This interaction occurs
at the bottom of the cleft that is formed between the
heavy and light chain and appears to be the most promi-
nent feature of the antigen-antibody interaction. The over-
all structure of CD40L is very similar to that of the uncom-
Figure 3. Amino Acid Sequence of the Heavy and Light Chains of
plexed CD40L. Thus, the neutralizing effect of the 5c8the Humanized 5c8 Antibody
antibody appears to be a consequence of steric blockingResidues of the CDR loops are underlined. The parts of the chains
of CD40L-CD40 interactions and not of any antibody-that have been modeled in the crystal structure are in bold. Residues
induced conformational changes. The solvent-accessi-of the CDR loops are underlined (the first underlined sequence seg-
ment is CDR H1; the second underlined sequence segment is CDR ble surface buried upon complexation of CD40L with
H2, etc.). CD40 has been predicted to be in the range of 834–1123
A˚2 [25, 11]. This is larger than the surface area of 765
A˚2 buried in the CD40L-5c8 Fab complex. The epitopeCDR L2 region of antibodies is frequently not involved
is a relatively flat region of the surface of CD40L, similarin binding [22]. Most of the buried surface area is contrib-
to what is seen with most protein antigens.uted by the heavy chain (61%). That is in agreement
Significant electron density is observed for the bian-with what is usually observed for antibodies [20, 22].
tennary complex–type carbohydrate that is attached toThe residues involved in contacts are S31(H), Y32(H),
residue N240 of CD40L. The carbohydrate chain is ac-and Y33(H) of CDR H1; N52(H), S54(H), D57(H), and
commodated within a large solvent channel, about 100 A˚N59(H) of CDR H2; R102(H) and N103(H) of CDR H3;
wide, of the crystal lattice. The electron density of theS31(L), S32(L), and Y36(L) of CDR L1; and S95(L) and
carbohydrate is not of sufficient quality to allow modelW96(L) of CDR L3. The contacts are mixed in character.
building of its residues, presumably due to disorder.There are several polar interactions; some of which in-
However, it is apparent that the carbohydrate formsvolve several main chain atoms, while others involve
extensive noncovalent interactions with the heavy chainside chain atoms (Figure 4). For example, the side chain
of the 5c8 antibody. Residues of the antibody that areof Y32(H) interacts with the side chain of S132 of CD40L,
within contact distance include Q43(H), E62(H), K63(H),and the side chain of D57(H) interacts with S248 of
and S66(H). These contacts may contribute to the energyCD40L. Also, the Od1 atom of the N55 side chain forms
of the interaction of 5c8 with CD40L. CD40L mutantan H bond with the carbonyl oxygen of Cys178 of CD40L.
N240Q, which lacks a carbohydrate, exhibits a reducedNo salt bridge interactions are found in the interface. In
level of immunoprecipitation with 5c8 antibody (Tableaddition, several aromatic residues (Y146 and H249 of
2). However, the level of expression of the mutant isCD40L; Y32 and Y33 of the heavy chain; and Y36 and
lower than wild type (WT), which makes it difficult toW96 of the light chain) contribute to van der Waals con-
ascertain whether or not the loss of the carbohydratetacts between CD40L and the antibody.
has a negative effect on 5c8 binding. Additionally, the
electron density map reveals that the carbohydrate in-
teracts with R207 of CD40L, a residue that has an impor-
tant contribution to the positive electrostatic potential
in its immediate region of the CD40L molecule [11].
A zinc ion was found to be located near the binding
site. It is coordinated by D100(H), D106(H), and E59(L),
and there are no direct contacts of the ion to CD40L.
This ion is not likely to play a functional role, and its
presence is probably a crystallization artifact.
Mutagenesis
The location and nature of the antigenic epitope was
studied by site-directed mutagenesis of CD40L. Muta-
tion sites that were selected included surface residues
in the vicinity of the putative CD40 binding site, residuesFigure 4. View of the CD40L-5c8 Interface
of the interfaces of two CD40L monomers, as well as
The CD40L backbone is represented as a yellow ribbon, and the H
residues involved in mutations associated with hyper-and L chains of 5c8 are represented as blue and red ribbons. Side
IgM syndrome (HIGMS). Residue substitutions includedchains of residues involved in CD40L-5c8 contacts are shown. The
dotted lines indicate H bonds. changes to alanine, charge reversal mutations, or
CD40L-5c8 Fab Complex Structure
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Table 2. Summary of mutagenesis dataa
Mutation 5c8 CD40-Fc Type
A123E 2 2 HIGMS
V126A 2 2 HIGMS
S128R 2 2 HIGMS (S128R/E129G)
E129G 2 2 HIGMS (S128R/E129G)
K133A 1 1 surface charge
W140G 2 2 HIGMS
E142K 1 1 murine residue
K143A 1/2 1/2 surface charge
G144E 1 2 HIGMS
Y145A 1/2 2 surface residue
L155P 2 2 HIGMS
Y170C 2 2 HIGMS
R203A 1 1/2 surface charge
I204A 1 1 monomer interface
R207A 1 1/2 surface charge
T211D 1 1 HIGMS
G227V 2 2 HIGMS
A235P 2 2 HIGMS
H249A 2 2 surface charge
T251A 1 1 monomer interface
T254M 2 2 HIGMS
F253A 2 2 monomer interface
G257S 2 2 HIGMS
a “1, 1/2, 2,” symbols indicate immunoprecipitation levels in com-
parison to WT.
“1,” symbol indicates a comparable signal.
“1/2,” symbol indicates a reduced but detectable signal.
“2,” symbol indicates a undetectable signal.
changes to other residues. Mutated full-length CD40L
was transiently expressed in its full-length membrane-
bound form. Expression of mutant CD40Ls was con-
Figure 5. Mutated Residues and the Antigenic Epitope
firmed with immunoprecipitation of detergent extracts
(a) The solvent-accessible surface shown with a dot surface repre-
from metabolically labeled cells with polyclonal antibod- sents the antigenic epitope. The two monomers of CD40L that are
ies directed against synthetic peptides from the N and shown are in space-filling representation and are colored blue and
C termini of CD40L [11, 23]. The ability of 5c8 antibody gray, respectively.
(b) Space-filling representation of CD40L indicating the position ofto bind to CD40L mutants was assessed by assaying
mutated residues. The effects of the mutations are color codedthe ability of CD40L mutants from detergent extracts to
according to the data for 5c8 binding in Table 2; green (1), yellowbe immunoprecipitated by 5c8 antibody. Similarly, the
(1/2), and red (2).
ability of CD40 to bind to CD40L mutants was assessed
by immunoprecipitation with CD40-Fc. CD40-Fc is a fu-
sion protein of the extracellular domain of CD40 and a middle of the epitope and interacts with Y33(H) of 5c8.
The mutation of residue E129 to glycine also results inhuman IgG Fc fragment. Table 2 summarizes data for
23 single residue mutations of CD40L. The effects for complete loss of immunoprecipitation. This residue is
observed to interact with N103(H) of 5c8 and its substitu-some of these mutations have been discussed before
in the context of the crystal structure of CD40L and tion with glycine results in loss of this interaction. As
we discuss further below, mutation E129G also resultsthe homology model of CD40 [11, 23]. Here, we present
additional mutations and their effects on 5c8 binding, in structural perturbations that may contribute to the
loss of immunoprecipitation. The substitution of otherwhich we interpret in the context of the crystal structure
of the CD40L-5c8 Fab. surface residues, such as K143, has a more intermediate
effect. Of interest is surface residue Y145, which doesThe mutation of surface residues of CD40L has an
effect on immunoprecipitation that, in general, corre- not form direct interactions with 5c8. However, mutation
Y145A has an intermediate effect on immunoprecipita-lates with the location of the antigenic epitope as deter-
mined from the crystal structure (Table 2; Figure 5). The tion with 5c8. The OH group of the side chain of Y145
interacts with the carbonyl oxygen of E230 of the adja-complete loss of immunoprecipitation due to mutation
H249A suggests that surface residue H249 may play cent CD40L monomer. This suggests that the residue
may also play a structure-stabilizing role that could ex-an important role in the energetics of the CD40L-5c8
interaction. This conclusion arises from the fact that the plain the observed effect on immunoprecipitation.
Most of the HIGMS mutations result in the completeCD40L-CD40 interaction surface is very extensive, and
loss of single residue side chains is not likely to result loss of ability of CD40L to be immunoprecipitated by
5c8 [23, 24]. Inspection of the crystal structure showsin complete loss of the interaction in most cases. The
crystal structure shows that residue H249 lies in the that most of the mutations of this type involve residues
Structure
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that are not directly involved with 5c8 interactions and
are more likely to play a structural role. For example,
residues A123, V126, W140, L155, Y170, A235, T254,
and G257 are buried residues and are likely to be impor-
tant for protein folding and stability. All hyper-IgM muta-
tions that affect 5c8 binding also affect CD40-Fc bind-
ing, which is consistent with the above hypothesis. It
appears that most HIGMS mutations affect the structue
locally, since it has been shown that these mutations
do not cause an alteration in structure that is sufficient
to completely prevent homotrimerization [23]. Interest-
ingly, most of the residues involved in known HIGMS
mutations form a cluster buried underneath the surface
area of the 5c8 epitope (Figure 5). This fact makes it
more likely that the structural perturbations induced by
the mutations propagate to the surface area of the epi-
tope and result in loss of 5c8 binding.
HIGMS double mutation S128R/E129G and single mu-
tation T211D are the only HIGMS mutations that involve
essentially exposed surface residues. Not only the dou-
ble mutation S128R/E129G, but also the single muta- Figure 6. Aggregated CD40L-5c8 on the Cell Surface
tions S128R and E129G result in complete loss of 5c8 (a) A model of the structure of aggregated CD40L-5c8 complexes on
the cell surface in ribbon representation. CD40L trimers are shown inand CD40-Fc binding (Table 2). Inspection of the crystal
light green, and 5c8 antibodies are shown in red. The horizontal barstructure shows that residue S128 does not interact at all
represents the cell membrane. A model of the Fc domain of the 5c8with 5c8; however, it stabilizes essential residue H249,
antibody has been included without the hinge linker.which interacts with Y33(H) of 5c8. Its substitution with
(b) A confocal microscopy image showing formation of patches of
arginine may disrupt this interaction, and the introduc- CD40L-5c8 on the surface of D1.1 cells. The red staining is Cy5-
tion of the positive charge may alter the local electro- conjugated anti-mouse IgG Fab fragment bound to murine 5c8 on
the cell surface. The green staining is Syto 13, a cell-permeablestatic potential. The other residue involved in the muta-
nucleic acid counterstain used to show the “outline” of the cell.tion, E129, interacts with N103(H) of 5c8 and also
stabilizes the conformation of K143 of CD40L, which
interacts with N103(H) of 5c8 (Figure 2). Its substitution
To test this prediction, we studied the binding of mu-with glycine results in loss of these interactions. Previ-
rine 5c8 antibody to CD40L on the cell surface. Indeed,ous studies have also shown that while mutant E129G
observations using confocal microscopy show that fluo-binds weakly to CD40-Fc, mutant E129A binds like wild
rescent 5c8 binding on the surface of cells expressingtype [24]. This suggests that the substitution of glycine
CD40L results in formation of single patches of aggre-introduces additional flexibility to the loop and may per-
gated CD40L-5c8 complexes (Figure 6b). The formationturb the structure of CD40L. Thus, the effect of the
of patches and caps is a phenomenon that is frequentlyE129G mutation on 5c8 binding is a combination of loss
observed with polyclonal antibodies, due to multiplicityof interactions and local perturbation of the structure,
of the antigenic epitopes [27, 28]. In the case of the 5c8which may result in loss of additional interactions. The
monoclonal antibody, clusters may be forming due to aT211D mutant behaves like wild type in terms of 5c8
high-avidity effect due to the multivalency of both anti-and CD40-Ig binding, and it has been concluded that
gen and antibody.the mutation is a polymorphism of the CD40L gene [23].
This residue is surface exposed and lies near the top of
Biological Implicationsthe pyramid, away from the epitope (Figure 5). Previous
crystallographic analysis has confirmed that the T211D
CD40L plays a central role in several activation path-mutant protein folds like wild type [23].
ways of the immune system. It belongs to the family of
TNF ligands, a group of trimeric proteins involved inPatch Formation
interactions with TNF family receptors that result in sig-The geometry observed for the CD50L-5c8 Fab complex
nal transduction events with pleiotropic effects. CD40Lwould be expected to favor formation of a cluster array
is responsible for immunoglobulin isotype switch andon the cell surface consisting of CD40L trimers linked
other B cell responses associated with antigen-pre-by whole 5c8 antibodies (Figure 6a). This is a conse-
senting cell (APC)-driven, T cell-mediated, B cell activa-quence of the fact that the long axis of the Fab is roughly
tion. Several monoclonal antibodies have been demon-normal relative to the three-fold axis of the CD40L trimer.
strated to block this interaction and its derivative roleThus, each 5c8 antibody molecule can interact with up
in vivo, and their usefulness as therapeutic agents isto two CD40L trimers, and each CD40L trimer can inter-
being tested.act with up to three 5c8 molecules. A hexagonal lattice
The crystal structure of CD40L in complex with theis expected to be the energetically favorable configura-
humanized antibody 5c8 Fab is the first available struc-tion for the array, although other types of imperfect lat-
ture of a TNF family member in complex with a neutraliz-tices may be possible due to the hinge flexibility of the
antibody molecules [26]. ing antibody Fab fragment. The structure shows that
CD40L-5c8 Fab Complex Structure
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(pH 7.0). Immobilized papain was added at an enzyme to substratethe antibody inhibits CD40L function by sterically
ratio of 1:50, and digestion was allowed to occur overnight at 378C.blocking the binding site of the CD40 receptor. This is
The immobilized papain was removed, and the crude digest wasconsistent with what was expected from mutagenesis
dialyzed against 20 mM sodium acetate buffer (pH 4.5). The Fab
studies. Presumably, effective blocking antibodies of fragment was separated from residual intact antibody, dimeric Fab
CD40L, such as 5c8, are selected for their ability to fragment, and Fc fragment by cation exchange chromatography
(Poros HS/M, PerSeptive Biosytems) with a shallow salt gradient.directly block the interaction with CD40. Of course, the
The 5c8 Fab fragment was then buffer exchanged into PBS bufferpossibility that antibody binding may prevent conforma-
(14.4 mM sodium phosphate dibasic, 5.6 mM sodium phosphatetional changes of CD40L that may be necessary for CD40
monobasic, and 150 mM NaCl) and purified further by size exclusionbinding cannot be discounted. However, comparison of
chromatography (Sephacryl S300, Pharmacia Biotech).
available TNF ligand structures and their complexes with Recombinant human-soluble CD40L consisting of residues 116–
receptors does not show evidence of significant global 261 was expressed and purified from a Pichia pastoris clone as
described previously [10]. The soluble CD40L was mixed with ex-conformational changes upon receptor binding [13, 29].
cess 5c8 Fab fragment and incubated at 378C for 15 min. The uncom-Also, in theory, it may be possible to identify an antibody
plexed 5c8 Fab fragment was separated from saturated CD40L-5c8that may sterically prevent the interaction of CD40L and
Fab complexes by size exclusion chromatography using a S200CD40 even when its epitope and the CD40 binding site
Sephacryl column (Pharmacia, GIBCO). The CD40L-5c8 Fab com-
do not overlap. This is a consequence of the large size plexes were futher concentrated to 10–15 mg/ml in PBS buffer using
of the antibody compared to that of the CD40L binding Centricon Plus-20 (Amicon Bioseparations, Millipore). The stoichi-
ometry of CD40L and the 5c8 Fab fragment in the saturated com-domain.
plexes was verified by SDS-PAGE analysis of the complexes withThe epitope of the antibody is located just above a
and without cross-linking reagent (J. L. and Y-M. H., unpublishedcluster of hydrophobic core residues whose mutation
data).has been associated with HIGMS. It has been proposed
that these mutations may cause structural perturbations
Preparation of Crystals
of a region of the surface that is important for receptor In order to find conditions of crystallization of the CD40L-5c8 Fab
binding [10]. It is interesting that the epitope of 5c8 complex, an incomplete factorial screen was set up using the Crystal
Screen kits from Hampton Research. Crystals were grown by vaporcoincides with the region of the surface that is most
diffusion at room temperature by mixing a reservoir solution of 20%likely to be perturbed by the mutations.
(w/v) PEG MME 550, 0.1 M MES (pH 6.5), and 0.01 M zinc sulfateThe crystal structure of the CD40L-5c8 Fab complex
with an equal volume of CD40L-5c8 Fab complex solution. Theshows that the complex maintains the symmetric tri-
crystals were thin and extremely fragile plates with dimensions 0.7 3
meric arrangement that characterizes the members of 0.7 3 0.02 mm. They grew within a few days and were easy to
the TNF family. It has been proposed, based on crystal- reproduce. Crystals were washed and dissolved, and the sample
was subjected to SDS electrophoresis, confirming that the crystalslographic evidence for dimerization of the TNF receptor,
consist of the CD40L-5c8 Fab complex.that the trimeric symmetry of the TNF family may facili-
Crystals were cryoprotected by soaking them in a solution con-tate the possible formation of clusters of ligand-receptor
taining 25% PEG 400, 20% PEG MME 550, 0.1 M MES (pH 6.5), andmolecules [14]. Aspects of this hypothesis are sup-
0.01 M zinc sulfate and freezing them in the liquid nitrogen gas
ported by recent evidence for CD40 receptor self- stream (21758C). The procedure of crystal annealing was performed
assembly in the absence of ligand [16]. Clustering of [31]. Crystals were quickly transferred after freezing into 0.3 ml 25%
PEG 400, 20% PEG MME 550, 0.1 M MES (pH 6.5), and 0.01 M zincTNF family molecules on the cell surface may act as an
sulfate at room temperature for 3 min and were frozen again in theamplifier of signaling and may be necessary due to the
liquid nitrogen gas stream.transient and two-dimensional nature of cell-cell interac-
tions. In the case of antibody binding to CD40L, the
Structure Determinationcluster formation may be an important contributor to
A native X-ray data set, up to 3.1 A˚ resolution, was collected from
the ability to inhibit due to the avidity effect and should a single crystal by using an R-AXIS II image plate detector system
be factored in when comparing affinities in cell-based (Molecular Structure). The data were integrated and reduced using
the HKL program package [32]. The data set was 96.1% completeassays versus in vitro assays. It may be interesting to
and had an Rmerge of 7.6%. Additional data statistics are includedexamine other biological effects that patch formation
in Table 1. Data processing indicated a monoclinic unit cell withmay have on T cells and their function.
approximate cell dimensions a 5 224.48 A˚, b 5 129.91 A˚, c 5
96.49 A˚, and b 5 109.68. The space group was identified as C2. The
Matthews volume [33] was 3.1 A˚3 Da21, assuming a complex of aExperimental Procedures
CD40L trimer and three Fab fragments in the asymmetric unit, with
a solvent content of 60.7%. The self-rotation function, calculatedProtein Preparation
cDNAs encoding the variable regions of the heavy and light chains with XPLOR [34], exhibited a strong peak for k 5 1208, which indi-
cated that a three-fold noncrystallographic symmetry axis that isof antihuman CD40L monoclonal antibody [30] were cloned from
total cellular RNA from the murine 5c8 hybridoma cells by RT-PCR. perpendicular to the ab plane of the unit cell exists.
Subsequent molecular replacement computing was done withFor humanization, the murine CDRs were grafted onto a homologous
human variable region framework, retaining murine residues the program AMoRe [35] from the CCP4 program package [36].
Molecular graphics manipulations were done with the programdeemed to be important in maintaining antigen binding (Figure 3).
The variable regions were fused to human constant regions (IgG1 QUANTA (Molecular Simulations). The coordinates of a trimer of the
extracellular domain of CD40L (PDB entry code 1aly) [10] were usedheavy chain and k light chain), and a vector for stable expression
of humanized 5c8 in NS0 myeloma cells was constructed. The cell as a probe for rotation and translation searches. The rotation search
gave a single solution with a correlation coefficient (cc) of 24.4,line was grown and the 5c8 was purified by conventional techniques
and shown to be biologically active. which was consistent with the three-fold axis predicted by the self-
rotation search. This solution was used for a translation search thatThe 5c8 Fab fragment was prepared from humanized 5c8 antibody
(hu5c8) using immobilized papain (Pierce); the intact humanized 5c8 yielded a single solution with a cc of 19.0 and an R factor of 50.7%.
Using rigid body refinement, these values refined to a cc of 20.0antibody was prepared at a concentration of 10 mg/ml in a buffer
containing 20 mM phosphate, 10 mM EDTA, and 25 mM cysteine and an R factor of 50.3%. Subsequently, searches for the 5c8 Fab
Structure
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fragments were done, keeping the CD40L solution fixed. A partially microscope (Leica Microsystems, Model TCS SP). A composite im-
age of the slices through the cells was generated using Leica TCS-refined crystal structure of the uncomplexed 5c8 Fab (to be de-
scribed elsewhere) was used as a search probe. The rotation search NT software.
produced several nonprominent peaks, including some related by
a three-fold axis. Translation searches for each of these peaks con- Acknowledgments
firmed that the peaks related by the three-fold axis correspond to
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